S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Bank Accounts: Frozen! (Ad)
Factory or farm? Oregon may alter land use for chipmakers
Travel disruption hits Germany on eve of transport strike
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Berlin climate proposal fails to get enough yes votes to win
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Turkmenistan votes for new, opposition-free parliament
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:CYTR

LadRx - CYTR Stock Forecast, Price & News

$0.09
+0.09 (+∞)
(As of 10/5/2022)
Add
Compare
Today's Range
$0.09
$0.10
50-Day Range
$0.08
$0.13
52-Week Range
$0.05
$0.86
Volume
4,000 shs
Average Volume
99,706 shs
Market Capitalization
$4.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CYTR stock logo

About LadRx (NASDAQ:CYTR) Stock

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

LadRx (NASDAQ:CYTR) Now Covered by Analysts at StockNews.com
LadRx Corporation Announces OTCQB Ticker Change to LADX
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
CytRx Corporation Relaunches as LadRx Corporation
European Patent Office Awards CytRx Key Patent
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
See More Headlines
Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LadRx and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTR
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$4.14 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Stephen Snowdy
    Chief Executive Officer
  • John Y. Caloz
    Chief Financial Officer, Treasurer & Senior VP
  • Felix Kratz
    Vice President-Drug Discovery
  • Cristina Newman
    Secretary













CYTR Stock - Frequently Asked Questions

How have CYTR shares performed in 2023?

LadRx's stock was trading at $0.0920 at the beginning of 2023. Since then, CYTR stock has increased by 0.0% and is now trading at $0.0920.
View the best growth stocks for 2023 here
.

What is LadRx's stock symbol?

LadRx trades on the NASDAQ under the ticker symbol "CYTR."

How do I buy shares of LadRx?

Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LadRx's stock price today?

One share of CYTR stock can currently be purchased for approximately $0.09.

How much money does LadRx make?

LadRx (NASDAQ:CYTR) has a market capitalization of $4.14 million.

How can I contact LadRx?

LadRx's mailing address is 11726 San Vicente Blvd Ste 650, Los Angeles, California 90049-5079. The official website for the company is www.cytrx.com. The company can be reached via phone at (310) 826-5648.

This page (NASDAQ:CYTR) was last updated on 3/27/2023 by MarketBeat.com Staff